跳至主要内容
临床试验/EUCTR2004-000655-41-ES
EUCTR2004-000655-41-ES进行中(未招募)1 期

A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor

ovartis Farmacéutica S.A0 个研究点目标入组 0 人开始时间: 2005年12月1日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • male and female adults between 6 and 60 months post renal transplantation, maintained for the last 6 months on the same triple immunussupressive regimen : CNI + MPA + corticosteroids or CNI + mTOR + corticosteroids
  • stable renal function and no history of rejection
  • PRA <10% pre-transplantation
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • patient at high immunological risk of rejection
  • pulse rate < 50bpm at screening
  • presence or history of second or third degree AV block
  • history of cardiac arrest
  • history of malignancy
  • systemic infection within 2 weeks prior to start study medication
  • HIV or hepatitis B surface Ag positive

研究者

发起方
ovartis Farmacéutica S.A

相似试验